Over the past five years. Developmental Funds have been used to support Pilot Projects, recruitment of new Investigators, and development of new Core Facilities to further UCCCC strategic goals, including expansion of population and translational research, immunotherapy, and interdisciplinary and interprogrammatic collaborations. From 2008-2012, a CCSG Investment of $1,519,611 has yielded a remarkable return of $33,870,022 In peer-reviewed support, as well as publications and programmatic development. Support for 10 new investigators has contributed to enhancements in the Molecular Mechanisms of Cancer, Hematopoiesis and Hematological Malignancies, Pharmacogenomics and Experimental Therapeutics and Cancer Prevention and Control Programs. With one exception, all of these faculty have remained at the institution and are active members of the UCCCC. Examples of significant recruitments include: Tina Shih, PhD, a cancer economist who is leading the development of cancer economics in the CPC Program;Jianjun Chen, PhD, whose research in genetic and epigenetic alterations in leukemia and lymphoma strengthens the HHM Program, and Peter O'Donnell, MD, who is applying his expertise in pharmacogenomics and its application to lead the 1200 Patient Trial. Four new developing Core Facilities were supported with CCSG developmental funds: Epidemiology and Research Recruitment Core (ERRC), Human Imaging Research Office (HIRO), Metabolomics, and the Biofluids Unit, the latter now a full component of the Pharmacology Core Facility. In addition, unique bioinformatics services (next-generation sequencing informatics) were added to the Biostatistics Core Facility, and have now been integrated into the institutional Bioinformatics Core (a developing UCCCC core). The developing cores continue to grow and have significantly contributed to interdisciplinary collaborations and translational research. Over the next grant period, we are requesting $360,000/year for: 1) recruitment of new investigators ($120K);2) Program development/Program Pilot Projects ($140K);and 3) development of new Core Facilities ($100K). These funds will be used to further the three components of our Strategic Plan: 1) the Personalized Cancer Care Consortium (PCCC);2) the Center for Cancer Prevention and Population Medicine;and 3) the Program in Cancer Survivorship, Cancer Economics, and Outcomes. We will support the ERRC, HIRO, Bioinformatics, and Metabolomics developing cores in the initial years of the next CCSG cycle. It is anticipated that as the needs for other new technologies are identified, CCSG developmental funds will be applied to their development.

Public Health Relevance

Developmental Funds represents a critical component of the CCSG used to further strategic initiatives. These funds are often combined with, and can be used to leverage, institutional and philanthropic support. They provide an Important mechanism for Program Leaders in the development of targeted research areas, enable UCCCC leadership to respond to the identification of new Core Facility needs, as well as influence institutional initiatives In recruitment and Facility development

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA014599-38
Application #
8486665
Study Section
Subcommittee G - Education (NCI)
Project Start
2013-04-01
Project End
2018-03-31
Budget Start
2013-04-23
Budget End
2014-03-31
Support Year
38
Fiscal Year
2013
Total Cost
$291,921
Indirect Cost
Name
University of Chicago
Department
Type
DUNS #
005421136
City
Chicago
State
IL
Country
United States
Zip Code
60637
Sharifi, Marina N; Mowers, Erin E; Drake, Lauren E et al. (2016) Autophagy Promotes Focal Adhesion Disassembly and Cell Motility of Metastatic Tumor Cells through the Direct Interaction of Paxillin with LC3. Cell Rep 15:1660-72
Drazer, Michael W; Stadler, Walter M (2016) The Role of Testosterone in the Treatment of Castration-Resistant Prostate Cancer. Cancer J 22:330-333
Epel, Boris; Redler, Gage; Pelizzari, Charles et al. (2016) Approaching Oxygen-Guided Intensity-Modulated Radiation Therapy. Adv Exp Med Biol 876:185-93
Sweis, Randy F; Medved, Milica; Towey, Shannon et al. (2016) Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a Pharmacodynamic Biomarker for Pazopanib in Metastatic Renal Carcinoma. Clin Genitourin Cancer :
Volden, Paul A; Skor, Maxwell N; Johnson, Marianna B et al. (2016) Mammary Adipose Tissue-Derived Lysophospholipids Promote Estrogen Receptor-Negative Mammary Epithelial Cell Proliferation. Cancer Prev Res (Phila) 9:367-78
Stein, Michelle M; Hrusch, Cara L; Gozdz, Justyna et al. (2016) Innate Immunity and Asthma Risk in Amish and Hutterite Farm Children. N Engl J Med 375:411-21
Baron, Beverly W; Baron, Rebecca M; Baron, Joseph M (2016) The Relationship between RUVBL1 (Pontin, TIP49, NMP238) and BCL6 in Benign and Malignant Human Lymphoid Tissues. Biochem Biophys Rep 6:1-8
King, Andrea C; Hasin, Deborah; O'Connor, Sean J et al. (2016) A Prospective 5-Year Re-examination of Alcohol Response in Heavy Drinkers Progressing in Alcohol Use Disorder. Biol Psychiatry 79:489-98
Appelbe, Oliver K; Zhang, Qingbei; Pelizzari, Charles A et al. (2016) Image-Guided Radiotherapy Targets Macromolecules through Altering the Tumor Microenvironment. Mol Pharm 13:3457-3467
Morrison, Gladys; Lenkala, Divya; LaCroix, Bonnie et al. (2016) Utility of patient-derived lymphoblastoid cell lines as an ex vivo capecitabine sensitivity prediction model for breast cancer patients. Oncotarget 7:38359-38366

Showing the most recent 10 out of 534 publications